Healthcare / Drug Manufacturers - Specialty & GenericNasdaqGS
$5.70
-0.45 (-7.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 31% · confianza 25%
FCF escenarios
weak_data · normalized FCF $4.8M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$85M
P/E
N/A
•EV/EBITDA
28.1x
↑ROE
-11.4%
↓Gross Margin
85.0%
↑Debt/Equity
0.41
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+0.1%
FCF CAGR
—
FCF margin
10.7%
FCF / Net income
-1.67x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $44.5M · net income $-2.8M · FCF $4.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $44.5M | $44.5M | $37.9M | $39.6M | $42.0M | $35.0M | $35.8M | $32.4M | $28.8M | $40.4M | $32.5M | $33.5M | $36.9M | $32.0M | $48.9M | $51.1M | $45.9M | $43.5M |
| Net Income | $-2.8M | $-2.8M | $-6.5M | $-6.3M | $-5.6M | $-3.5M | $-3.3M | $-3.5M | $-7.0M | $-8.0M | $-944683.00 | $731351.00 | $2.4M | $-2.1M | $5.8M | $5.7M | $2.5M | $3.1M |
| EBITDA | $3.0M | $3.0M | $182422.00 | $2.5M | $332919.00 | $-3.1M | $-1.6M | $-4.9M | $-8.2M | $-1.4M | $963777.00 | $3.4M | $5.5M | $-2.5M | $9.7M | $10.9M | $7.5M | $6.6M |
| EPS | -0.19 | -0.19 | -0.46 | -0.44 | -0.38 | -0.24 | -0.22 | -0.23 | -0.45 | -0.50 | -0.06 | 0.04 | 0.14 | -0.11 | 0.30 | 0.28 | 0.12 | 0.17 |
| Gross Margin | 85.0% | 85.0% | 82.6% | 84.7% | 78.3% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -6.3% | -6.3% | -17.0% | -24.2% | -13.6% | -21.9% | -17.8% | -28.7% | -38.8% | -10.1% | -4.4% | 3.3% | 9.6% | -11.9% | 18.1% | 19.3% | 14.2% | 13.3% |
| Net Margin | -6.4% | -6.4% | -17.1% | -15.9% | -13.3% | -10.0% | -9.3% | -10.9% | -24.2% | -19.8% | -2.9% | 2.2% | 6.6% | -6.6% | 12.0% | 11.1% | 5.4% | 7.1% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.41 | 0.41 | 0.90 | 0.62 | 0.58 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 0.95 | 0.95 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $4.8M | $4.8M | $-791900.00 | $5.6M | $6.4M | $6.2M | $5.3M | $2.8M | $2.7M | $-833674.00 | $438606.00 | $5.7M | $6.5M | $648714.00 | $6.7M | $8.5M | $-230497.00 | $-196832.00 |
| Returns | ||||||||||||||||||
| ROE | -11.4% | -11.4% | -28.4% | -21.2% | -15.4% | -8.2% | -7.1% | -6.9% | -12.5% | -12.4% | -1.3% | 1.0% | 3.0% | -2.6% | 6.8% | 6.8% | 3.2% | — |
| Valuation | ||||||||||||||||||
| EV/EBITDA | 28.08 | 28.08 | 191.57 | 12.93 | 109.91 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 3.40 | 3.40 | 1.42 | 1.08 | 0.98 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 17.6% | 17.6% | -4.3% | -5.9% | — | -2.2% | 10.6% | 12.5% | -28.7% | 24.3% | -3.1% | -9.2% | 15.2% | -34.4% | -4.5% | 11.5% | 5.4% | — |
| EPS Growth | 58.7% | 58.7% | -4.5% | -15.8% | — | -9.1% | 4.3% | 48.9% | 10.0% | -733.3% | -250.0% | -71.4% | 227.3% | -136.7% | 7.1% | 133.3% | -29.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.46 → -0.19
Residual
+14.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.